Skip to content

Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer

Feasibility and Acceptability of a Remote Time-Restricted Eating and Mindfulness-Based Stress Reduction Intervention to Reduce Risk Factors Associated With Early-Onset Colorectal Cancer Development Among Young Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06022887
Acronym
MBSR&TRE
Enrollment
43
Registered
2023-09-05
Start date
2023-10-18
Completion date
2024-07-24
Last updated
2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer, Microbial Colonization, Obesity, Stress, Psychological, Time Restricted Feeding

Keywords

obesity; Time Restricted Feeding; microbiome; chronic stress

Brief summary

The goal of this clinical trial is to evaluate the feasibility of remote time-restricted eating (TRE) and mindfulness-based stress reduction (MBSR) interventions and the preliminary effect on EOCRC-related markers. The main question\[s\] it aims to answer are: * Is it feasible and acceptable to conduct 8-week remote interventions of TRE, MBSR, and combined TRE+MBSR among young adults with excess adiposity and moderate-to-severe perceived stress? * Will participants in the combined group lose more body weight and reduce their stress levels than those in the remaining groups? * Will participants in the combined group experience better body composition changes and improve their cardiometabolic health compared to those in the remaining groups? * Will participants in the combined group exhibit changes in the microbiome compared to those in the remaining groups? Participants will: * Complete 8 weeks of a TRE intervention * Complete 8 weeks of a remote MBSR intervention Researchers will compare 1. TRE alone; 2. MBSR alone; 3. TRE + MBSR; and 4. Control to see if the study is feasible and acceptable; to see if individuals lose body weight; to see if individual stress levels reduce; to see changes in the microbiome.

Detailed description

Early onset colorectal cancer (EOCRC) is defined as a diagnosis of colorectal cancer (CRC) in patients younger than 50 years old. The American Cancer Society reported that 12% of all CRC diagnoses as occurring in individuals younger than 50 years old. Worldwide, a steady increase in EOCRC cases is observed among Westernized countries, which suggests that similar risk factors and exposures within these developed countries are contributors to EOCRC. In particular, increased adiposity from an early age that persists through adulthood and chronic psychosocial stress are under investigation as drivers of the recent uptick in EOCRC in the United States (US) and other Westernized countries. Obesity in early adulthood is strongly associated with increased risk of EOCRC; in the US, obesity affects 42% of adults. In addition, obesity is associated with metabolic, hormonal, and immune perturbations that can promote gene mutations that drive EOCRC tumorigenesis. Chronic stress can negatively impact several different systems of the human body including the sympathetic nervous system (SNS)-related catecholamines, epinephrine and norepinephrine, and hypothalamic-pituitary-adrenal (HPA)-axis related hormones including adrenocorticotropic hormone and the glucocorticoid, cortisol. Due to the broad impact that exposure to chronic stress has in the human body, chronic stress has been linked to several diseases, including cancer. The gut and the brain are connected through a bidirectional system coined the gut-microbiota-brain axis (GMBA). Chronic stress can disrupt the SNS, HPA-axis and immune system, leading to a shift in gut microbial ecology and metabolic function that tips the balance to a more pro-inflammatory colonic state conducive to the formation of EOCRC. This study will examine if mitigating chronic stress and weight loss can modify EOCRC risk in young adults at risk of EOCRC. Accumulating evidence suggests that time-restricted eating (TRE), a type of intermittent fasting, produces a \ 300-500 kcal/d energy deficit by limiting an individual's daily eating window to 4-8 hours each day. Mindfulness meditation is the practice of cultivating a moment-to-moment awareness of internal and external experience in an accepting and open manner. In 1990, Kabat-Zinn developed Mindfulness Based Stress Reduction (MBSR): an intervention with a goal of reducing stress, pain, and suffering. MBSR is associated with lower perceived stress and decreased circulating cortisol concentrations. Existing evidence suggests that MBSR also yields EOCRC preventive effects specific to body weight reduction, increase of insulin sensitivity and reduction of inflammation. We propose to conduct an 8-week 4-arm randomized-controlled study of 1. TRE alone; 2. MBSR alone; 3. TRE + MBSR; and 4. Control among 40 young adults with obesity (BMI ≥ 30 kg/m2) and moderate to severe perceived stress (Perceived Stress Score ≥14) to evaluate the feasibility of the interventions and preliminary effect on EOCRC-related markers. Data generated from this preliminary trial would serve in developing a fully powered efficacy trial testing TRE+MBSR for EOCRC prevention among young adults in the Chicagoland area.

Interventions

BEHAVIORALTRE

daily ad libitum food intake, 8-h 12pm - 8pm, 8 wks active weight loss phase;

BEHAVIORALMBSR

Completed 30 sessions of a Mindfulness-Based Stress Reduction (MBSR) interventions for 8 weeks

Sponsors

University of Illinois at Chicago
CollaboratorOTHER
Lisa Tussing-Humphreys
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

1. 18-39 years old. 2. BMI 30-49.99 kg/m2. 3. Own and use a smartphone, computer, or tablet with access to the Internet. 4. Score ≥ 14 on the Perceived Stress Score (PSS) at screening.

Exclusion criteria

1. Have a personal or family history of EOCRC. 2. Have taken antibiotics in the previous 2 months. 3. Have an inflammatory bowel disease or genetic predisposition to EOCRC or CRC (e.g., Lynch syndrome);. 4. Any cancer diagnosis or cancer treatment in the past 12 months. 5. Consume \>50 grams ethanol daily (approximately 4-5, 12 ounces beers). 6. Use combustible tobacco. 7. Have history of bariatric surgery or bowel resection. 8. Have an active infection. 9. Have type 1 or type 2 diabetes, immunodeficiency/autoimmune disorder, or inflammatory bowel disease. 10. Use fiber or pre-/probiotic supplements \>3 days per week. 11. Currently taking corticosteroids medication - inhaled, topical, or oral in the past 2 months (affects cortisol measures). 12. Are on a weight-loss diet or involved in a formal weight-loss program or are not weight stable for 3 months (+/- 4.5 kg) prior to the study. 13. Females who are pregnant/trying to become pregnant. 14. Have schizophrenia (medication can affect study outcomes). 15. Have an eating window of \<10 hours/day or are currently following an intermittent fasting pattern. 16. Night shift workers (shift passes midnight). 17. Present a history of eating disorder. 18. Currently taking weight loss medication. 19. Illegal drug use in the past month (not marijuana).

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of the studyBaseline; through study completion, an average of 9 weeksthe number of people interested in the study, those who pass phone and in-person screenings, and those who decline enrollment and their reasons. Once enrolled, we will closely monitor attendance, data completeness, session attendance, asynchronous intervention usage, and loss to follow-up/withdrawal. To monitor participant progress, we will update the CONSORT participant flow diagram every week. Participants who withdraw voluntarily will be asked for their reasons.
Acceptability of the studyWeek 4 of the intervention; through study completion, an average of 9 weeksParticipants will complete the acceptability of intervention measure (scores range from 4-20 points with higher scores reflecting higher acceptability).

Secondary

MeasureTime frameDescription
Serum cortisolBaseline; through study completion, an average of 9 weeksObjective stress markers will be measured via serum cortisol.
Serum norepinephrineBaseline; through study completion, an average of 9 weeksObjective stress markers will be measured via serum norepinephrine
Perceived Stress Scale.Screening; through study completion, an average of 9 weeksThe Perceived Stress Scale queries participants' perceptions of feeling stress during the last month. Responses were on a 5-point scale from never to very often. Scores will be summed to indicate current stress levels, with higher scores suggesting greater perceived stress (≥ 14 indicates moderate to high perceived stress).
Body fat massBaseline; through study completion, an average of 9 weeksBody fat mass will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan.
Body lean massBaseline; through study completion, an average of 9 weeksBody lean mass will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan.
Hair cortisolBaseline; through study completion, an average of 9 weeksObjective stress markers will be measured via hair cortisol
TriglyceridesBaseline; through study completion, an average of 9 weeksWill be measured from plasma by a commercial lab.
High sensitivity C-reactive protein.Baseline; through study completion, an average of 9 weeksWill be measured from plasma by a commercial lab.
homeostasis model assessment-insulin resistance (HOMA-IR)Baseline; through study completion, an average of 9 weekscalculated from fasting glucose and insulin using a standard formula.
Microbial Deoxyribonucleic acid (DNA) isolation: 16S on V4 regionBaseline; through study completion, an average of 9 weeksperformed on stool using Microbial DNA isolation
Body bone densityBaseline; through study completion, an average of 9 weeksBody bone density will be measured via whole body dual energy x-ray absorptiometry (DEXA) scan.
Serum adrenocorticotropic hormone (ACTH)Baseline; through study completion, an average of 9 weeksObjective stress markers will be measured via serum ACTH.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026